Emilio Gamez
Research Subjects
Research Interests
Emilio Gamez has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Andreu Comas
Department of Microbiology, School of Medicine, Universidad Autonoma de San Luis Potosi.;School of Medicine, Universidad Cuahutemoc, San Luis Potosi, S.L.P., Mexico, Mexico
1 shared publication - Cesar Ulises Monjaras-Avila
Department of Oncological Cinical Research, CREO Cancer Center, San Luis Potosí, S.L.P., Mexico., Mexico
1 shared publication - Cinthya Portales
Department of Radiation Oncology, CREO Cancer Center, San Luis Potosi, S.L.P., Mexico, Mexico
1 shared publication - Dante Guillermo Mejía-Torres
Department of Medical Oncology, CREO Cancer Center, San Luis Potosí, S.L.P., Mexico., Mexico
1 shared publication - Dukagjin Blakaj
Department of Radiation Oncology, Professor and Vice Chair of Clinical Operations, The Ohio State University Comprehensive Cancer Center, Columbus, OH., USA
1 shared publication - Kenneth Hu
New York University, New York, NY, USA
1 shared publication
Latest Publications
- Open Access
- 7 January 2026
- Published by MDPI AG in Preprints.org
Integrating Digital Health into Oncology: A Comprehensive Review
Background/Objectives: Digital health encompasses telemedicine, mobile health (mHealth), wearable technologies, big data analytics, artificial intelligence (AI), machine learning (ML), and immersive technologies. In oncology, where care is complex, multidisciplinary, and longitudinal, these tools offer opportunities to enhance prevention, early detection, treatment planning, patient–clinician communication, survivorship, and palliative care. However, inconsistent definitions and ongoing ethical, regulatory, and implementation challenges hinder optimal integration. This review aims to synthesize current evidence on digital health in oncology and examine its applications across the cancer care continuum. Methods: A comprehensive narrative review of peer-reviewed literature was conducted, including clinical studies, trials, and systematic reviews evaluating digital health technologies in oncology. Evidence was organized according to key phases of the cancer care continuum, from prevention and diagnosis to treatment delivery, survivorship, and end-of-life care. Results: Digital health applications extend beyond virtual consultations. AI- and ML-driven systems support diagnostics, medical imaging, genomics, and treatment planning, while mHealth applications and wearable devices enable real-time symptom monitoring, toxicity reporting, and long-term follow-up. Digital education and communication platforms improve shared decision-making and patient engagement. Across diverse oncology settings, these tools demonstrate feasibility, high patient and clinician satisfaction, and potential improvements in care coordination and efficiency. Nevertheless, challenges related to data quality, interoperability, privacy, algorithmic bias, equity of access, and regulatory oversight persist. Conclusions: Digital health is increasingly embedded across the oncology care continuum and holds substantial promise for advancing personalized, patient-centred cancer care. Continued multidisciplinary collaboration, robust clinical validation, and responsible governance are essential to ensure safe, equitable, and clinically meaningful global implementation.
- 7 January 2026
- Published by MDPI AG in Preprints.org
Open AccessIntegrating Digital Health into Oncology: A Comprehensive Review
Background/Objectives: Digital health encompasses telemedicine, mobile health (mHealth), wearable technologies, big data analytics, artificial intelligence (AI), machine learning (ML), and immersive technologies. In oncology, where care is complex, multidisciplinary, and longitudinal, these tools offer opportunities to enhance prevention, early detection, treatment planning, patient–clinician communication, survivorship, and palliative care. However, inconsistent definitions and ongoing ethical, regulatory, and implementation challenges hinder optimal integration. This review aims to synthesize current evidence on digital health in oncology and examine its applications across the cancer care continuum. Methods: A comprehensive narrative review of peer-reviewed literature was conducted, including clinical studies, trials, and systematic reviews evaluating digital health technologies in oncology. Evidence was organized according to key phases of the cancer care continuum, from prevention and diagnosis to treatment delivery, survivorship, and end-of-life care. Results: Digital health applications extend beyond virtual consultations. AI- and ML-driven systems support diagnostics, medical imaging, genomics, and treatment planning, while mHealth applications and wearable devices enable real-time symptom monitoring, toxicity reporting, and long-term follow-up. Digital education and communication platforms improve shared decision-making and patient engagement. Across diverse oncology settings, these tools demonstrate feasibility, high patient and clinician satisfaction, and potential improvements in care coordination and efficiency. Nevertheless, challenges related to data quality, interoperability, privacy, algorithmic bias, equity of access, and regulatory oversight persist. Conclusions: Digital health is increasingly embedded across the oncology care continuum and holds substantial promise for advancing personalized, patient-centred cancer care. Continued multidisciplinary collaboration, robust clinical validation, and responsible governance are essential to ensure safe, equitable, and clinically meaningful global implementation.